MedTrace Logo

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

NCT00002460 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.

PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer.

Conditions

Interventions

DRUG

goserelin acetate

DRUG

tamoxifen citrate

PROCEDURE

ablative endocrine surgery

PROCEDURE

oophorectomy

Sponsors & Collaborators

Principal Investigators

  • Michael Baum, MD, ChM, FRCS · University College London Hospitals

Study Design

Purpose
TREATMENT

Eligibility

Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1987-09-30

Countries

  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002460 on ClinicalTrials.gov